You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞盛醫藥(06855.HK在研新藥抑制劑之臨床試驗申請獲美國批准
阿思達克 06-15 08:58
亞盛醫藥集團(06855.HK)公布,公司在研原創新藥Bcl-2抑制劑APG-2575的臨床試驗申請獲美國食品藥品管理局(美國FDA)許可,將展開單藥或與抗癌藥物聯合治療晚期ER+乳腺癌或實體瘤的研究。

該研究是一項全球多中心、開放性、Ib/II期臨床研究,旨在評估APG-2575單藥治療晚期實體瘤患者,或聯合CDK4/6抑制劑palbociclib治療CDK4/6抑制劑治療後進展或復發的ER+/HER2-轉移性乳腺癌患者的安全性、耐受性、藥代動力學特徵及初步療效。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account